# X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-leerink-global-healt-0a237ea1
Ticker: XFOR
Company: X4 Pharmaceuticals
Source: X4 Pharmaceuticals
Published: 2026-03-04 12:00 EST
## Summary

X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology...

## Article Body
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.

A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations .

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com .

X4 Investor Contact: Remy Bernarda Jenny Kobin IR Advisory Solutions ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-07 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--477fc08a) — Source: X4 Pharmaceuticals
- 2026-07-01 11:00 EST — [X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-it-316d9f27) — Source: X4 Pharmaceuticals
- 2026-06-01 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f8e34e98) — Source: X4 Pharmaceuticals
- 2026-05-27 11:00 EST — [X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2) — Source: X4 Pharmaceuticals
- 2026-05-06 11:15 EST — [X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-cor-86158817) — Source: X4 Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)